[en] OBJECTIVES: To understand current thinking and clinical decision-making in the treatment and management of patients with mild-to-moderate ulcerative colitis (UC). METHODS: This multinational, survey-based study was conducted in 2021. Two meetings were held, involving 11 IBD specialists, that used a series of questions and discussion to identify all factors possibly related to the management of UC. The importance of identified factors was assessed using an online questionnaire covering three scenarios - active disease, remission and patient empowerment. Each factor was scored on a scale of 0 (very-unimportant) to 100 (very-important) within each scenario, by a separate group of healthcare professionals working in IBD. RESULTS: A total of 157 individual factors were identified by the 11 IBD specialists and scored in the three scenarios by 56 respondents (52; 93% specialist gastroenterologists) from Europe and North America (25; 45%), South America (19; 34%) and the Middle East, Asia and Australia (12; 21%). For all scenarios, factors related to educating patients regarding UC and its treatment and understanding of patient goals ranked highest, ahead of clinical considerations regarding disease activity and treatment history. Setting realistic short-term treatment targets was a key consideration. 5-ASA optimisation and use of faecal calprotectin monitoring were core strategies across the three scenarios tested. Support for patients during longer-term management of their disease, starting from initial flare, was an important recurring theme. CONCLUSION: The current management approach for mild-to-moderate UC was found to be guided primarily by the patient's perspectives and goals, alongside assessment of their medical and disease history.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Dignass, Axel U ; Department of Medicine I, Agaplesion Markus Hospital, Goethe-University
Paridaens, Kristine ; Ferring International Center, St-Prex, Switzerland.
Al Awadhi, Sameer; Department of Gastroenterology, Rashid Hospital, Dubai Health Authority, Dubai,
Begun, Jakob ; Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Australia.
Cheon, Jae Hee ; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul
Fullarton, John R ; Violicom Medical Limited, Aldermaston, UK.
Louis, Edouard ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive ; Hepato-Gastroenterology and Digestive Oncology Department, University and Centre
Magro, Fernando; Department of Biomedicine, Unit of Pharmacology and Therapeutics, University of ; Department of Gastroenterology, São João University Hospital, Porto, Portugal.
Marquez, Juan Ricardo; Instituto de Coloproctologia, ICO Clinica Las Americas, Medellin, Colombia.
Moschen, Alexander R; Department of Internal Medicine, Gastroenterology and Hepatology, Kepler
Narula, Neeraj; Division of Gastroenterology, Department of Medicine and Farncombe Family
Rydzewska, Grazyna ; Clinical Department of Internal Medicine and Gastroenterology with Inflammatory ; Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Travis, Simon P L ; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS
Solberg IC, Lygren I, Jahnsen J, IBSEN Study Group, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population based inception cohort (IBSEN study). Scand J Gastroenterol. 2009; 44 (4): 431–440.
Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019; 114 (3): 384–413.
Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018; 16 (3): 343–356.
Harbord M, Eliakim R, Bettenworth D, European Crohn’s and Colitis Organisation [ECCO], et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017; 11 (7): 769–784.
Ko CW, Singh S, Feuerstein JD, American Gastroenterological Association Institute Clinical Guidelines Committee, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019; 156 (3): 748–764.
Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020; 8 (8): CD000543.
Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020; 8 (8): CD000544.
Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin. 2021; 37 (11): 1891–1900.
Sandborn WJ, Feagan BG, Hanauer SB, et al. The guide to guidelines in ulcerative colitis: interpretation and appropriate use in clinical practice. Gastroenterol Hepatol (NY). 2021; 17 (4 Suppl 4): 3–13.
Ungaro R, Colombel J-F, Lissoos T, et al. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol. 2019; 114 (6): 874–883.
Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110 (9): 1324–1338.
Colombel J-F, D'haens G, Lee W-J, et al. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2020; 14 (2): 254–266.
Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021; 160 (5): 1570–1583.
Solitano V, D’Amico F, Fiorino G, et al. Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis. JCM. 2020; 9 (9): 2905.
Nguyen NH, Fumery M, Dulai PS, et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018; 3 (11): 742–753.
Gisbert JP, Gomollón F, Hinojosa J, et al. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. J Crohns Colitis. 2010; 4 (5): 567–574.
Carbonell-Estrany X, Dall’Agnola A, Fullarton JR, et al. Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS]). Acta Paediatr. 2018; 107 (5): 854–860.
Wu C-Y, Yang H-Y, Luo S-F, et al. From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. IJMS. 2021; 22 (2): 686.
Campbell L, Pepper T, Shipman K. HbA1c: a review of non-glycaemic variables. J Clin Pathol. 2019; 72 (1): 12–19.
Louis E. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. J Crohns Colitis. 2015; 9 (1): 1–3.
Honig G, Heller C, Hurtado-Lorenzo A. Defining the path forward for biomarkers to address unmet needs in inflammatory bowel diseases. Inflamm Bowel Dis. 2020; 26 (10): 1451–1462.
Barberio B, Segal JP, Quraishi MN, et al. Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis. 2021; 15 (7): 1184–1196.
Flourié B, Hagège H, Tucat G, MOTUS Study Investigators, et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther. 2013; 37 (8): 767–775.
Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009; 7 (7): 762–769.
Rubin DT, Sninsky C, Siegmund E, et al. International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS survey. Inflam Bowel Dis. 2021; 27 (12): 1942–1953.
Mitchell R, Kremer A, Westwood N, et al. Talking about life and IBD: a paradigm for improving patient-physician communication. J Crohns Colitis. 2009; 3 (1): 1–3.
Irving P, Burisch J, Driscoll R, et al. IBD2020 global forum: results of an international patient survey on quality of care. Intest Res. 2018; 16 (4): 537–545.
Danese S, Banerjee R, Cummings JRF, et al. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i support therapy-access to rapid treatment (iSTART) approach. Intest Res. 2018; 16 (4): 522–528.
Pedersen N, Thielsen P, Martinsen L, et al. EHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014; 20 (12): 2276–2285.
Moshkovska T, Stone MA, Smith RM, et al. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011; 17 (9): 1874–1881.
Lees CW, Regueiro M, Mahadevan U. Innovation in inflammatory bowel disease care during the COVID-19 pandemic: results of a global telemedicine survey by the international organization for the study of inflammatory bowel disease. Gastroenterology. 2020; 159 (3): 805–808.e1.
Martinez-Vinson C, Le S, Blachier A, et al. Effects of introduction of an inflammatory bowel disease nurse position on healthcare use. BMJ Open. 2020; 10 (5): e036929.
Furnham A. Response bias, social desirability and dissimulation. Pers Individ Dif. 1986; 7 (3): 385–400.
